We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Immunodiagnostic Systems Holdings Plc | IDH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 378.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 378.00 |
| Top Posts |
|---|
Posted at 13/8/2020 18:53 by faz You cannot buy and sell in any quantity. What investor buys shares he/she cannot sell? Today I would bet many holders have used the opportunity to get out while they can. The company would be better off going private if it won't do anything to sponsor liquidity in its shares. |
Posted at 20/6/2020 20:30 by hedgehog 100 Thanks for that 2toptrader.The negative impact of the lockdown on laboratory testing is very temporary, and we're already emerging from it. It will soon be forgotten. Whereas the massive need for COVID-19 testing will be ongoing, and this is what investors here will now focus on. And in this respect, IDH are planning to launch a range of COVID-19 antibody tests by the end of this month (i.e. the first quarter of their financial year), which could hardly be much more near-term : 17/06/2020 07:00 UKREG Immunodiagnostic Systems Hldgs PLC Final Results " ... Jaap Stuut, CEO of IDS, commented: "During FY2020 we delivered a second consecutive year of like for like revenue growth, with revenue increasing by 2% to GBP39.3m. We also increased the number of analysers sold or placed to 150, compared to 127 in FY2020. Adjusted EBITDA improved to GBP6.1m from GBP4.8m in the prior year. Our results in Q1 of FY2021 will be significantly impacted by reduced laboratory testing volumes, however once the pandemic subsides, we believe we are in a strong position to continue our revenue growth. Additionally, we have an opportunity to commercialise our range of automated and manual SARS-CoV-2 antibody testing kits, which we plan to launch during June 2020. ... In the short term we will also focus on commercialising opportunities arising from Increased levels of SARS-CoV2 antibody testing using a range of automated and manual test kits which we expect to launch during Q1 FY2021. ..." |
Posted at 12/6/2020 09:00 by farukequity whoever is running PR & Investor Relations department in this business should be fired on the spot. keeping things under wraps is not how you create shareholder value in the 21st century. imagine if they issued an announcement initially they are working on a quantitative antibody test & leveraging all the unique advantages of their underlying business - the share price would be 2-3x higher before today's announcement already.hope they are doing Zoom calls with media & institutions 24 f...ing 7 right now to make people aware of what they have. for all of the small retail investors like yours truly, at least they are at the top of today's leader boards, so thousands of people will be looking at this company and scratching their heads just like me. these guys have the final product, distribution network and unit economics all ready - and the explosive share price rise is just beginning |
Posted at 22/4/2020 15:16 by hedgehog 100 Speaking of Omega Diagnostics, its share price has been doing rather well recently, multibagging from 7.625p at the start of this month to its current share price of 31p.Fueled by announcements that it is to manufacture COVID-19 tests. And IDH looks like it will also be entering into such agreements shortly, judging from its recent trading update. But the market doesn't seem to have picked up on this yet. Probably because IDH is currently 'under the radar screen' of most investors, and the RNS was released after close on Friday (17th. April). 17/04/2020 16:35 UKREG Immunodiagnostic Systems Hldgs PLC FY20 Trading Update " ... Cash position Closing cash and cash equivalents were GBP27.6m at 31 March 2020 (31 March 2019: GBP27.7m). ... Looking forward So far in April 2020 we have seen a reduction in revenue versus the same period last year, caused by a reduction in routine medical testing in hospitals and laboratories as their focus has been on COVID-19 treatment and testing. IDS intend to take appropriate action, including utilising the various schemes available from governments to provide business support, to minimise our costs during this period of uncertainty. From a liquidity perspective, IDS is in a very strong position with cash holdings of almost GBP28m. We are offering our production facilities, and sales network, to several new and existing partners who are in the process of developing COVID-19 test kits. ... " |
Posted at 08/3/2012 19:15 by dugganjoe think investors are giving that dodgy bunch a wide berth after the profit warnings |
Posted at 25/1/2012 06:53 by mw16 The point i make is that there are a lot of ifs and buts. Investors are focusing on the negative instead of the positive.The company has proven stellar growth over last 5 years, they always find a way to grow. |
Posted at 24/1/2012 15:23 by masurenguy A more bullish view today from LCF Research. I've no position in IDH but now on my watchlist after the large fall in price over the past 6 months. Letter from the Editor Ben Graham is considered to be the first proponent of value investing and has been credited by Warren Buffett as being a major influence on his investment approach. Graham observed that: "In the short term, the stockmarket behaves like a voting machine, but in the long term it acts like a weighing machine. In the long term, true value will be reflected in the stock price. The investor is best off concentrating on the real life performance of his companies and receiving dividends, rather than being too concerned with Mr Market's often irrational behaviour." The share price performance in recent months of Immunodiagnostics Systems Holdings, in which I have a holding, is a good illustration both of the above observations and also of the opportunities thrown up for private investors who choose to invest with the mindset of long term owners. It also illustrates the inherent weaknesses of the UK's capital markets processes in supporting the development of the sort of Mittelsand companies which the UK economy so badly needs. Here are some salient features: The share price has moved from 800p (mkt cap £225m) in August 2010 to a high of 1218p (mkt cap £345m) in August 2011 to a price of 291.5p (mkt cap of £82.6m) on 23rd January 2012. The price drop in Autumn 2011 was occasioned by the impact of increased competition in the Vitamin D market. The company had told the market during the previous year that increased competition would occur and had also, in my opinion, outlined a sound strategy for mitigating over the medium term the effects of increasing competition. A former senior investment banker tells me that as the market cap rose to its high in August 2011, it passed certain trigger points which brought in new institutional investors. However, as the market cap fell, it triggered the need to sell on the part of those investors. As readers will know, my views on the ability of the marketmaking system to provide a stabilising influence under such circumstances are unprintable! In my opinion the company did not articulate its strategy for being a growth stock as clearly as it could have done at the time of its November 2011 interim results announcement. The commercial reality of developing a long term business does not always occur as a straight line process, fitting neatly into accounting periods, which makes it essential to communicate strategy very succinctly particularly when trading is challenging. Looking at the company's track record since listing on AIM in 2004, it has demonstrated the ability to identify some excellent strategic acquisitions and to be able to execute on challenging projects embracing science, engineering and markets. These skills do not evaporate over night. I and several investors whom I know who have a Ben Graham mindset are currently increasing our IDS shareholdings. It is a style of investing which is akin to a salvage tug patiently waiting for the valuable 'wrecks' which Mr Market insists upon delivering from time to time! Charles Breese: Editor |
Posted at 16/12/2011 12:00 by praipus Hi IDH BB,Newton Investment Management like IDH collecting 5.35%! For anyone who likes to follow deep value/activist investors I'm tracking their holdings in post 9 on the WAM thread: |
Posted at 21/7/2010 17:23 by steadyitgoes When Roger Duggan brought his company to AIM in 2004, investors bought in at 51p per share. This month, stock in Immunodiagnostic Systems Hldgs (LON:IDH) was changing hands at 800p. For the company's chief executive, the "astonishing" upward trajectory has followed a period of dramatic change for the diagnostic testing specialist, which is currently embarking on a major new offensive to sell a new generation of immunoassay kits to even larger markets.....More here - |
Posted at 20/7/2010 09:11 by philo124 Not unusual given the quantity sold/bought; it will be interesting who they letin, should see RNS before too long; maybe US investors. Puts floor price under shares IMO |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
